3/18/2014 9:17:17 AM
MECHELEN, Belgium, March 18, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) will present favorable pre-clinical data on GLPG1790 in triple-negative breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on 7 April 2014. In the abstract, Galapagos disclosed that GLPG1790 is the first selective small molecule inhibitor of the ephrin receptor kinase family, which could play a key role in melanoma, pancreatic, ovarian, prostatic, and colorectal cancers, in addition to triple-negative breast cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by